QDEL - QUIDEL CORP /DE/

21.48
-1.120   -5.214%

Share volume: 989,714
Last Updated: 03-03-2026
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances: 0.01%

PREVIOUS CLOSE
CHG
CHG%
$22.60
-1.12
-0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
60%
Profitability 66%
Dept financing 11%
Liquidity 15%
Performance 77%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-5.54%
1 Month
-26.71%
3 Months
-22.79%
6 Months
-22.71%
1 Year
-44.88%
2 Year
-51.55%
Key data
Stock price
$21.48
P/E Ratio 
2.82
DAY RANGE
$20.59 - $21.96
EPS 
$8.52
52 WEEK RANGE
$19.50 - $41.40
52 WEEK CHANGE
-$45.85
MARKET CAP 
2.841 B
YIELD 
N/A
SHARES OUTSTANDING 
67.235 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-30-2025
BETA 
0.40
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,105,493
AVERAGE 30 VOLUME 
$1,319,251
Company detail
CEO: Douglas C. Bryant
Region: US
Website: www.quidel.com
Employees: 7,000
IPO year: 1992
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances
Sector: Manufacturing

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of drugs of abuse.

Recent news